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Background. Surgical stress triggers an inﬂammatory response and releases mediators into human plasma such as interleukins
(ILs). Awake craniotomy and craniotomy performed under general anesthesia may be associated with diﬀerent levels of stress. Our
aim was to investigate whether those procedures cause diﬀerent inﬂammatory responses. Methods. Twenty patients undergoing
craniotomy under general anesthesia and 20 patients undergoing awake function-controlled craniotomy were included in
this prospective, observational, two-armed study. Circulating levels of IL-6, IL-8, and IL-10 were determined pre-, peri-, and
postoperativelyinbothpatientgroups.VASscoresforpain,anxiety,andstressweretakenatfourmomentspre-andpostoperatively
to evaluate physical pain and mental duress. Results. Plasma IL-6 level signiﬁcantly increased with time similarly in both groups.
No signiﬁcant plasma IL-8 and IL-10 change was observed in both experimental groups. The VAS pain score was signiﬁcantly
lower in the awake group compared to the anesthesia group at 12 hours postoperative. Postoperative anxiety and stress declined
similarly in both groups. Conclusion. This study suggests that awake function-controlled craniotomy does not cause a signiﬁcantly
diﬀerent inﬂammatory response than craniotomy performed under general anesthesia. It is also likely that function-controlled
craniotomy does not cause a greater emotional challenge than tumor resection under general anesthesia.
Copyright © 2009 Markus Klimek et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
General anesthesia using endotracheal intubation is the
standard procedure during brain tumor resection. Vital
parameters are monitored and intubation provides a safe
airway; drugs ensure analgesia and suppress vegetative
reactions. Immobilization is relatively simple, even for
patients in an atypical position. However, the use of general
anesthesia precludes intraoperative monitoring of higher
brain functions, and lesions made to the central nervous
system being detected when reversibility of damage control
might still be possible. Therefore, awake function-controlled
neurosurgerymaybebeneﬁcialinthatrespect.Duringawake
craniotomy, the cerebral cortex of the patient is electrically
stimulated. This allows the surgeon to properly identify
and spare functionally relevant areas of the brain. Awake
craniotomy has been shown to be a well-tolerated procedure
with minimal side eﬀects. Nevertheless, it is considered to be
more challenging for the patient. By allowing for maximal
tumor excision while keeping healthy tissue intact, awake
craniotomy has the potential for better patient outcomes [1]
In such a procedure, the need to provide suﬃcient analgesia
and sedation without interfering with electrophysiological
monitoring is essential [2].
Before, during, and after craniotomy all patients are
confronted with anxiety, stress, and pain. These factors
can all negatively inﬂuence the perioperative experience.
Patients undergoing craniotomy using general anesthesia,
however,havetoendureadditional physicalstressfactorslike
intubation, longer hospital stays, and mechanical ventilation
[3].
Patient perspectives regarding awake brain surgery have
been investigated and adequate preoperative consultation
has been found to be essential for patient conﬁdence. In2 Mediators of Inﬂammation
addition, scalp incisions and ﬁxation of pin-holding sites
were regarded as major sources of pain and discomfort. Still,
the beneﬁts far outweigh those of general anesthesia because
awake craniotomy patients report less pain, anxiety, and fear
[4, 5]. Even though there are drawbacks, the majority of
patients tolerate awake craniotomy very well.
No study has attempted to compare the inﬂammatory
impact of awake craniotomy versus general anesthesia proce-
dures. Pathological inﬂammatory states can have far ranging
clinical eﬀects and negatively inﬂuence a patient’s neurolog-
ical outcome [6–8]. Recent research has demonstrated that
cytokine levels can be correlated to the degree of brain tissue
manipulation [9]. Plasma cytokine levels could reﬂect stress-
related biochemical pathways after surgery [10–12].
Cytokines orchestrate the complex network of cellular
interaction that regulate both cellmediated and humoral
immunity, as well as the acute phase response [13].
Cytokines are glycopeptide signaling molecules that act
at extremely low concentrations, mediating key immune
responses. Several cytokines are released during periods
of stress, including interleukin-6 (IL-6), IL-8, and IL-10
[14]. IL-6 is a proinﬂammatory cytokine secreted by T-
cells, macrophages, and other cells. IL-6 is involved in
both the immune response to trauma and the acute phase
response; its targets being T- and B-cells. IL-8 is a chemokine
produced mainly by macrophages and epithelial cells and
functions to attract neutrophiles towards inﬂammation sites.
These proinﬂammatory cytokines play a key role in the
physiological response to trauma and surgery, whereas IL-
10 is an anti-inﬂammatory cytokine produced by Th2-cells
thatcauseareductioninproinﬂammatorycytokinesynthesis
[15].
Our aim was to investigate whether awake function-
controlledcraniotomycausesasigniﬁcantlydiﬀerentinﬂam-
matory response than craniotomy performed under general
anesthesia. We thought both procedures would create similar
inﬂammatoryproﬁlesdespite diﬀeringanesthesiatechniques
used. In order to test our hypothesis, plasma levels of
IL-6, IL-8, and IL-10 were measured during the pre-,
peri-, and postoperative periods in both patient groups. We
also noted corresponding subjective outcome parameters for
pain, anxiety, and stress to investigate whether performing
an awake procedure causes more physical pain and mental
duress.
2. Patientsand Methods
2.1. Study Design and Inclusion Criteria. This was a prospec-
tive, single centre, two-armed observational study with 40
patients(20menand20women).Theprotocolwasapproved
by the Medical Ethics Committee of the Erasmus Medi-
cal Center, Rotterdam. All procedures were performed in
accordance with the Helsinki declaration. Written informed
consent was obtained from all patients.
Plasma cytokine determinations were performed
blinded, but randomization was limited. The decision
to perform either function-controlled awake craniotomy
or craniotomy under general anesthesia was determined
by the neurosurgeon who based his decision on the
(
p
g
/
m
L
)
1
10
100
Pre-operative Open
dura
Closed
dura
p.o.12hrs p.o.24hrs
General anesthesia
Awake function-controlled anesthesia
Figure 1: Box plots of plasma IL-6 levels. A signiﬁcant IL-6 level
increase is found in both experimental groups F(1.336, 49.416) =
24.148, P<. 001. No signiﬁcant plasma IL-6 level diﬀerence is
found between groups.
intracerebral location of the tumor. The type or size (WHO
classiﬁcation of brain tumors) had no inﬂuence on whether
or not awake craniotomy was chosen. By proxy patients
were allocated to the general anesthesia group unless the
location of the tumor warranted the beneﬁts of an awake
procedure. Patients with tumors close to functional relevant
a r e a sl i k et h em o t o rc o r t e xo ra r e a sr e l a t e dt os p e e c h
require the awake monitoring made possible by the awake
craniotomy procedure. By allocating these patients to the
awake craniotomy group maximal tumor resection is made
possible with a minimal risk of functional neurological
damage.
Eligible patients were >18 years of age and were under-
going craniotomy for an intracerebral tumor. Patients were
excluded if they were (1) ASA-classiﬁcation IV-V, (2) did not
provide written informed consent, (3) had a tumor location
other than intracerebral, (4) had surgery beginning later
than 11:00 a.m., (5) had a disease of the endocrine system
or (6) were taking drugs that alter endocrine metabolism
(like thyroxine). Noncooperative or noncompliant patients
could be withdrawn from the study, as could patients who
developed serious adverse eﬀects.
2.2. Anesthesia Procedure. Patients in both groups received
1.5 mg lorazepam on the evening before the surgery.
All patients were on a regimen of dexamethasone 4 ×
4mg/day with the ﬁrst dose given at least one day prior
to surgery; regular personal drug regimens were continued
during the study. In the awake function-controlled group,
7.5mg piritramide and 25mg promethazine were given
30 minutes prior to induction. In the general anesthesiaMediators of Inﬂammation 3
group, premedication consisted of 50mg promethazine. In
both groups propofol was administered for sedation and
remifentanil for analgesia. The general anesthesia group
received an additional 0.25mg fentanyl before intubation
and placement of the Mayﬁeld clamp. Cis-atracurium was
used for muscle relaxation prior to intubation. In order
to provide adequate pain control during awake craniotomy
patients were inﬁltrated with bupivacaine 0.375% with
adrenaline 1 : 200000 at the site of scalp incision. Postopera-
tively all patients were oﬀered 4 times one gram paracetamol
per day, and if required, supplemental morphine.
2.3. Outcome Measures. Patient characteristics, medications
used during and after surgery, ﬂuid balance, and duration
of surgery were documented. Pain, anxiety, and stress were
measured at 12 and 24 hours pre- and postoperatively, using
visual analogue scale (VAS) scores (0 = none, 10 = extreme).
EDTA blood samples (7mL) for cytokine level determi-
nations were collected preoperatively, during the opening
and closing of the dura, and 12 and 24 hours postoperatively.
Plasma was isolated by centrifugation at 2650gmax for
10 minutes at 20
◦C; samples were stored at −80
◦C until
assay.
Enzyme immunoassays for the quantitative determina-
tion of human IL-6, IL-8, and IL-10 were performed with a
sandwich ELISA (Pelikine Compact and additional Pelikine
Toolset,Sanquin,Amsterdam,TheNetherlands)asdescribed
previously [16]. Data were calculated as pg/mL plasma and
presented in Figures 1, 2,a n d3 as (log) pg/mL.
2.4. Statistical Analysis. Data were analyzed using SPSS for
Windows, version 16.0.1. The independent sample t-test was
used to compare means for patient demographics (excluding
ASA classiﬁcation) and perioperative characteristics. The
Pearson Chi-square test was used to evaluate diﬀerences in
ASA classiﬁcation. All data were reported as the mean (SD),
counts, or median (25%–75%).
Sample size was calculated using the O’brien-Shieh Algo-
rithm for the MANOVA repeated measures test. Assuming a
medium eﬀect, an eﬀect size of 0.6 was used and a power of
0.8. There were two experimental groups and 5 repetitions.
The required a priori sample size computed by this method
was 39.
For the VAS scores and cytokine data the MANOVA
test was used. Diﬀerences in VAS score or cytokine values
between the experimental groups across all time points and
interaction between experimental groups and time were
analyzed using multivariate repeated measures. Experimen-
tal group and time were the independent variables. When
Mauchly’sTestofSphericitywassigniﬁcant,theGreenhouse-
Geisser test of within subjects eﬀects was used. When
a signiﬁcant diﬀerence was found between experimental
groups a one-way ANOVA test with posthoc multiple
comparisons(Bonferronicorrection)wasusedtoanalyzethe
relationship between the cytokines or VAS scores from the
ﬁrst preoperative measurement until 24hours postoperative.
The same Bonferroni correction was employed to analyze
diﬀerences between experimental groups and time.
A P-value < .05 was considered statistically signiﬁcant.
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Figure 2: Box plots of plasma IL-8 levels.I L - 8l e v e l sd on o t
signiﬁcantlychangethroughouttimeforbothexperimental groups.
No signiﬁcant diﬀerence in plasma IL-8 levels is found between
groups.
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Figure 3: Box plots of plasma IL-10 levels. IL-10 levels do not
signiﬁcantlychangethroughouttimeforbothexperimental groups.
No signiﬁcant diﬀerence in plasma IL-10 levels is found between
groups.
3. Results
Forty patients were included in the study. The awake
function-controlledandgeneralanesthesiagroupscontained4 Mediators of Inﬂammation
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Figure 4: Box plots of pain, anxiety, and stress. (a)Pain. A signiﬁcant increase in pain is experienced in both experimental groups F(2.290,
80.165) = 24.642, P<. 001. A signiﬁcant diﬀerence F(1, 35) = 7.632, P = .009 was observed in the awake group compared to the general
anesthesia group at “p.o.12 hours” (a). (b)Anxiety. A signiﬁcant decrease in anxiety is experienced in both experimental groups F(1.982,
69.362) = 4.637, P = 0.013.(c)Stress. A signiﬁcant decrease in stress is experienced in both experimental groups F(2.426, 84.911) = 7.920,
P< . 001.
20 patients each, stratiﬁed for gender (10 males and 10
females).Nosigniﬁcantintergroupdiﬀerenceswereobserved
for age, height, weight, ASA classiﬁcation, or Hb concentra-
tion (Table 1).
Perioperative characteristics are described in Table 2.
As expected, the total amount of propofol administered
throughout the operation was signiﬁcantly less in the awake
group than in the general anesthesia group. The general
anesthesia group also received more crystalloids during the
operation. The total amount of remifentanil used in the
general anesthesia group was 8.4 ± 5.4mg. No more than
200μg of remifentanil was given to the awake craniotomy
group.
Plasma concentrations of IL-6, IL-8, and IL-10 during
all time points are displayed in Figures 1 through 3.I L - 6
level signiﬁcantly increased with time in both experimental
groups (main eﬀect of time: F(1, 49) = 24.1, P<. 001,
observed power = 1.00). However, there were no diﬀerences
between groups (group-time interaction: F(1, 37) = 1.3, P =
.3, observed power = 0.20). Furthermore, IL-8 levels did not
signiﬁcantly change with time in both experimental groups
(main eﬀect of time: F(1, 48) = 2.2, P = .1, observed power
= 0.35) and no signiﬁcant IL-8 diﬀerences between groups
(group-time interaction: F(1, 37) = 2.8, P = .1, observed
power = 0.37). The same applied for IL-10 levels, there were
no signiﬁcant change with time in both experimental groups
(maineﬀectoftime:F(1,39) =2.6,P = .1,observedpower =
0.36) and no signiﬁcant diﬀerences between groups (group-
time interaction: F(1, 37) = 0.6, P = .4, observed power =
0.12).Mediators of Inﬂammation 5
Table 1: Patient demographics.
General anesthesia Function-controlled
Age (years) 48 ± 15.4 44 ± 13.2
Gender m/f 10/10 10/10
Height (cm) 174 ± 11.3 176 ± 9.6
Weight (kg) 74 ± 16.5 81 ± 14.7
ASA classiﬁcation 1/2/3 (number of patients) 9/10/1 5/15/0
Hb concentration (mmol/L) 9.3 ± 19 . 0 ± 0.6
Data presented as mean ± SD
Table 2: Perioperative characteristics.
General anesthesia Function-controlled
Propofol during operation (mg) 3277 ± 1632 673 ±313a
Operation time (min) 327 ± 104 275 ± 56
Blood loss during operation (L) 400 (300 – 500) 450 (300 – 600)
Colloids during operation (L) 500 (500 – 500) 500 (0 – 500)
Colloids after operation (L) 0.05 ± 0.2 0.1 ± 0.4
Crystalloids during operation (L) 3.7 ± 2.0 1.6 ±0.7a
Crystalloids after operation (L) 2.0 ± 1.0 2.0 ± 0.9
Urine during operation (mL) 1620 (1043 – 2050) 1042 (480 −1483)
b
Urine after operation (mL) 1759 ± 836 1668 ± 620
Remifentanil 8.4 ± 5.4mg 200 μg∗
Postoperative paracetamol (mg) 2100 ± 1483 1900 ± 1477
Postoperative morphine (mg) 1.60 ± 4.72 2.00 ± 5.48
Function-controlled versus general anesthesia signiﬁcantly decreased: aP<. 001 and bP = .004.Data presented as mean ± SD and median (25%–75%).
∗Maximum total amount of boluses given.
There was no signiﬁcant diﬀerences between groups in
the amount of postoperative morphine and paracetamol
used. The mean subcutaneous postoperative morphine
administered in the general anesthesia group was 1.60
(±4.72mg), while the mean given to the awake group
was 2.00 (±5.48mg). The mean postoperative paracetamol
administered to the general anesthesia group was 2100
(±1483mg), while the mean given to the awake group was
1900 (±1477mg).
Painincreasedsigniﬁcantlywithtimeinbothexperimen-
t a lg r o u p s( m a i ne ﬀect of time: F(2, 80) = 24.6, P<. 001).
However, a signiﬁcant diﬀerence between groups (F(1, 35) =
7.6, P = .009) was noted with the awake group having less
pain at the 12 hours postoperative time point (Figure 4).
Anxiety signiﬁcantly decreased with time in both exper-
imental groups (main eﬀect of time: F(2, 69) = 4.6, P =
.013) and there was a signiﬁcant stress decrease with time in
both experimental groups (main eﬀect of time: F(2, 85) =
7.9, P<. 001.)
4. Discussion
We believe we arethe ﬁrst to comparethe cytokine proﬁlesof
awake and general anesthesia craniotomy groups. Cytokine
release is also a known physical reaction to tissue damage.
The inﬂuence of surgery on cytokine plasma levels has been
addressed during several studies. There is a great amount
of evidence linking IL-6 to the degree of surgical trauma
[17–22]. In addition, there are also studies that establish
a clear relationship between dynamic IL-6 changes and
cortisol plasma levels during the perioperative period [11,
23]. The nonsigniﬁcant diﬀerences in IL-6 levels between
groups found during this experiment suggest from an
immunological perspective that both procedures are likely
to be similarly stressful for the body. However, the low and
medium observed power of our negative ﬁndings requires a
larger patient group to provide more certainty.
It is interesting to note the signiﬁcant plasma IL-6
increase despite the exact dexamethasone 4 × 4mg/day
regime given to both experimental groups. Another study
investigatingtheeﬀectsofdexamethasoneproduceddiﬀerent
results. Morariu et al. found that after receiving dexametha-
sone (1mg/kg) before anesthesia induction, plasma levels of
both IL-6 and IL-8 were signiﬁcantly reduced, while levels of
IL-10 increased perioperatively [24].
Our ﬁnding that there was a signiﬁcant plasma IL-
6 increase throughout time for both experimental groups
and a signiﬁcant increase in reported pain can be partially
explained by the expected increase in pain after tissue dam-
age. It is noteworthy that an increasing pain trend matches
the increasing IL-6 tendency observed. The important role
interleukin-6 plays in nociception and the pathophysiology
of pain during a variety of diﬀerent conditions might explain
this trend [25] .As t u d yd o n ew i t hr a tm o d e l so b s e r v e d
that higher IL-6 concentrations were linked to more intense
hyperalgesia [26].6 Mediators of Inﬂammation
Recently, plasma IL-8 has been measured as a key
mediator for neuroinﬂammation in patients with severe
traumatic brain injuries [27]. Central venous plasma IL-8
levels were signiﬁcantly lower in survivors than in nonsur-
vivors. In our study, the insigniﬁcant in-between and within-
subject plasma IL-8 change in both experimental groups was
unexpected.DuetoIL-8’spresenceinneutrophils,microglia,
astrocytes and endothelial cells of the brain [28–31]w e
expected damaged brain tissue to cause an increased release
of IL-8 over time from these sources. However, the studies
involving traumatic brain injury patients contain a diﬀerent
patient population then ours and diﬀerent confounders.
The additional hypoxia and ischemia experienced in these
severely injured traumatic brain injury patients can be
attributed to shock and resulting hypoperfusion and might
account for increased plasma IL-8 levels [32].
Awake craniotomy is considered a stressful procedure.
It seems logical that being awake while a neurosurgeon
removes pathological brain tissue would lead to a more
intense emotional response than undergoing the same
procedure under general anesthesia. However, perhaps good
psychological support and active coping mechanisms may
actually make awake craniotomy less stressful for the patient.
This might be due to the awake group having decreased
feelings of dependency and loss of control than those in the
general anesthesia group.
Our results show that patients undergoing awake
function-controlled craniotomy experience less 12 hours
postoperative pain than their general anesthesia coun-
terparts. The intensive preoperative consultation patients
received might have inﬂuenced results due to the subjective
natureoftheVASscoringsystem[33].Itcouldbearguedthat
perioperativemedicationmayalsohaveinﬂuencedVASscore
results. Patients who underwent awake function controlled
craniotomy received 25mg of promethazine and 7.5mg
of piritramide 30 minutes before surgery. In comparison,
general anesthesia patients received 50mg of promethazine
and two boluses of fentanyl, one prior to induction and
another prior to placement of the Mayﬁeld clamp. Pir-
itramide and fentanyl are both opiates with additive sedative
and euphoric properties. They are also accepted drugs for
surgical procedures like craniotomy [34]. Additionally, the
seven and six hours half life of piritramide and fentanyl
make them unlikely to aﬀect the ﬁrst postoperative VAS
score measurement taken at 12 hours postoperative [35, 36].
We think that the local anesthesia provided by bupivacaine
inﬁltrationatthesiteofscalpincisionwastheprimaryreason
why VAS scores were signiﬁcantly lower in the awake group.
The diﬀering nature of awake craniotomy and general
anesthesia techniques requires a larger amount opiates to be
giventothegeneralanesthesiagroup.Thereissomeevidence
thatopiatescanmodulatetheimmunesystem[37–39].How-
ever, our results reveal similar pro- and anti-inﬂammatory
proﬁles for both groups with no signiﬁcant diﬀerence having
been found between groups. It is still important to consider
that the larger opiate amount given to the general anesthesia
groupcouldhavealtereditsimmunologicalproﬁle.However,
the aim of this study is to compare the inﬂammatory proﬁle
of two diﬀerent anesthesia techniques. General anesthesia
cannot be performed without a greater amount of opiates
being used by the anesthesiologist.
The smaller amount of propofol administered to the
awake group is due to the reduced need for sedation during
the awake craniotomy procedure. On the other hand, the
larger amount of crystalloids given to the general anesthesia
group can be explained by the need to counteract the
vasodepressive properties of propofol (Table 2).
A limitation of our study is that for ethical reasons
allocation of patients to one group or another could not be
randomized. This restriction could bias our results. However
keeping the previously mentioned limitations in mind,
the plasma levels of pro- and anti-inﬂammatory cytokines
measured during this study suggests that awake function-
controlled craniotomy does not cause a signiﬁcantly dif-
ferent inﬂammatory response than craniotomy performed
under general anesthesia. Furthermore, the nonsigniﬁcant
diﬀerence in subjective outcome parameters for pain (with
exception 12 hours postoperative), anxiety, and stress insin-
uates that both procedures are equally mentally challenging.
Therefore, it is likely that function-controlled craniotomy
does not cause a greater inﬂammatory insult or emotional
challenge than patients undergoing tumor resection using
general anesthesia.
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